These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35764907)

  • 41. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
    Tangchitpianvit K; Rattarittamrong E; Chai-Adisaksopha C; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Tantiworawit A; Norasetthada L
    Hematology; 2021 Dec; 26(1):355-364. PubMed ID: 33853503
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma.
    Yuan X; Yu T; Huang Y; Jiang H; Xu X; Liang Y; Qian W
    Sci Rep; 2022 Dec; 12(1):21541. PubMed ID: 36513674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
    Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
    Ekenel M; Iwamoto FM; Ben-Porat LS; Panageas KS; Yahalom J; DeAngelis LM; Abrey LE
    Cancer; 2008 Sep; 113(5):1025-31. PubMed ID: 18618509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience.
    Zektser M; Rabinovich A; Grinbaum U; Porges T; Gozlan A; Gourevitch A; Al-Athamen K; Barrett O; Peles I; Kaisman-Elbaz T; Levi E
    Isr Med Assoc J; 2022 Oct; 24(10):654-660. PubMed ID: 36309861
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
    Schorb E; Fox CP; Kasenda B; Linton K; Martinez-Calle N; Calimeri T; Ninkovic S; Eyre TA; Cummin T; Smith J; Yallop D; De Marco B; Krampera M; Trefz S; Orsucci L; Fabbri A; Illerhaus G; Cwynarski K; Ferreri AJM
    Br J Haematol; 2020 Jun; 189(5):879-887. PubMed ID: 31997308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
    Bairey O; Taliansky A; Glik A; Amiel A; Yust-Katz S; Gurion R; Zektser M; Porges T; Sarid N; Horowitz NA; Shina TT; Lebel E; Cohen A; Geiger KR; Raanani P; Wolach O; Siegal T
    Cancer; 2023 Dec; 129(24):3905-3914. PubMed ID: 37572086
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients.
    Sanders S; Chua N; Larouche JF; Owen C; Shafey M; Stewart DA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1505-1510. PubMed ID: 30965138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Specific KIR-HLA genotypes predict outcomes in refractory or relapsed primary central nervous system lymphoma.
    Lin Z; Xu H; Ma J; Ma Y; Li Q; Kang H; Zhang M; Chen B
    Hematology; 2023 Dec; 28(1):2243424. PubMed ID: 37545411
    [TBL] [Abstract][Full Text] [Related]  

  • 51. R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience.
    Lee JY; Paik JH; Suh KJ; Kim JW; Kim SH; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Lee JS; Lee JO
    Blood Res; 2021 Dec; 56(4):285-292. PubMed ID: 34801986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.
    Birsen R; Willems L; Pallud J; Blanc E; Burroni B; Legoff M; Le Ray E; Pilorge S; Deau B; Franchi P; Vignon M; Kirova Y; Edjlali M; Houillier C; Soussain C; Varlet P; Dezamis E; Damotte D; Bouscary D; Tamburini J
    Haematologica; 2018 Jul; 103(7):e296-e299. PubMed ID: 29472354
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
    Wang XX; Huang HQ; Bai B; Cai QQ; Cai QC; Gao Y; Xia YF; Xia ZJ; Jiang WQ
    Leuk Lymphoma; 2014 Nov; 55(11):2497-501. PubMed ID: 24605911
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
    Desai AV; Li Y; Getz K; Seif AE; Fisher B; Huang V; Aplenc R; Bagatell R
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27372. PubMed ID: 30070014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
    Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
    Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
    Suzuki Y; Imoto N; Ishihara S; Fujiwara S; Ito R; Sakai T; Yamamoto S; Sugiura I; Kurahashi S
    Intern Med; 2022 May; 61(9):1345-1352. PubMed ID: 34670884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China.
    Sun X; Wu Y; Xing R; Bai X; Qian J; Zhu H; Cui Q; Chen Y; Liu Q; Lai W; Li J; Wang Y; Sun S; Gao C; Ji N; Liu Y
    Front Oncol; 2022; 12():792274. PubMed ID: 35280789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New approaches in primary central nervous system lymphoma.
    Fraser E; Gruenberg K; Rubenstein JL
    Chin Clin Oncol; 2015 Mar; 4(1):11. PubMed ID: 25841718
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.
    Harjama L; Kuitunen H; Turpeenniemi-Hujanen T; Haapasaari KM; Leppä S; Mannisto S; Karjalainen-Lindsberg ML; Lehtinen T; Eray M; Vornanen M; Haapasalo H; Soini Y; Jantunen E; Nousiainen T; Vasala K; Kuittinen O
    Acta Oncol; 2015 Jun; 54(6):939-43. PubMed ID: 25761092
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
    Salamoon M; Hussein T; Kenj M; Bachour M
    Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.